Needham Maintains Buy on Taysha Gene Therapies, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $5 to $7.
March 20, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies and raises the price target from $5 to $7.
The upgrade in price target by a reputable analyst like Gil Blum from Needham suggests a strong confidence in Taysha Gene Therapies' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100